Pharma News

New research presented at the annual Congress of the European Alliance of Associations for Rheumatology (EULAR) suggests that continuing urate-lowering therapy (ULT) remains the most effective strategy for maintaining remission in patients with gout, although some patients may successfully remain symptom-free after discontinuing treatment.

In a move aimed at improving access to diabetes and obesity treatment, Alkem Laboratories has launched India's first semaglutide single-shot pre-filled syringes, with prices starting at just ₹350.

The launch marks another milestone in the rapidly evolving obesity and diabetes care market, as Alkem continues to expand its semaglutide portfolio following the introduction of pre-filled disposable and reusable injection pens earlier this year.

Gilead Sciences has announced positive results from its Phase 3 IDEAL trial evaluating Livdelzi (seladelpar)in adults with primary biliary cholangitis (PBC), a rare chronic autoimmune liver disease. The study met its primary endpoint, demonstrating statistically significant improvement in a composite measure of alkaline phosphatase (ALP) normalization compared with placebo.

The Serum Institute of India (SII) has joined hands with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo strain of Ebola virus, a deadly pathogen currently driving outbreaks in the Democratic Republic of Congo (DRC) and Uganda. CEPI has committed up to 8.6 million USD to support the vaccine's advancement toward clinical testing.

Prescribing antibiotics for common sore throats may have only a minimal impact on preventing serious streptococcal infections, according to new research from the University of Gothenburg. The findings challenge a widely debated rationale for antibiotic use and highlight the importance of recognizing early signs of severe illness instead.

The U.S. Food and Drug Administration (FDA) has approved Xocova (ensitrelvir), developed by Japanese pharmaceutical company Shionogi & Co., for the prevention of COVID-19 following exposure to an infected individual. The approval makes Xocova the first and only oral antiviral therapy authorized in the United States for post-exposure prophylaxis of COVID-19.

A new review suggests that routinely prescribing antibiotics after hospital discharge may provide little benefit for children recovering from complicated acute appendicitis (CAA). The findings add to growing concerns about unnecessary antibiotic exposure and its potential role in adverse effects and antimicrobial resistance.

Researchers from The University of Osaka have developed an innovative mRNA-based treatment that could help protect the heart from long-term damage following a heart attack. In a new study, scientists found that delivering a combination of five therapeutic mRNAs directly to damaged heart tissue significantly improved heart function and survival in mice that had experienced myocardial infarction (heart attack).